What does Hemant Surgical do?

Hemant Surgical Industries Ltd is a Micro Cap company in the Healthcare Services sector, specializing in medical equipment and supplies. It was incorporated in 1989 and became a public company in 1994, with a market cap of Rs 96 Cr and no recent sales or profit data reported.

Overview:<BR>Hemant Surgical Industries Ltd is engaged in the business of Medical Equipment & Supplies and operates within the Healthcare Services industry, classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as "Hemant Surgical Industries Private Limited" on March 27, 1989, and later converted to a public limited company, changing its name to "Hemant Surgical Industries Limited" on February 22, 1994. There is no recent sales or profit data reported.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: Rs 96 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 12.00<BR>Industry P/E: 54<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.12<BR>Return on Equity: 14.82%<BR>Price-to-Book: 1.76<BR><BR>Contact Details:<BR>Registrar Address: Not available.

When is the next results date for Hemant Surgical?

No Upcoming Board Meetings

Has Hemant Surgical declared dividend?

No Dividend History Available

What is the technical trend for Hemant Surgical?

As of June 3, 2025, Hemant Surgical's trend has shifted to bearish, driven by daily moving averages and Bollinger Bands indicating bearish momentum, despite a mildly bullish MACD signal on the weekly chart.

As of 3 June 2025, the technical trend for Hemant Surgical has changed from mildly bearish to bearish. The current stance is bearish with moderate strength, primarily driven by the daily moving averages indicating bearish momentum and the Bollinger Bands showing a bearish signal on both weekly and monthly time frames. The Dow Theory also supports a mildly bearish outlook on the weekly and monthly charts. While the MACD shows a mildly bullish signal on the weekly, it is not strong enough to counter the overall bearish indicators. The stock has underperformed significantly against the Sensex over multiple time frames, further reinforcing the bearish sentiment.

Who are the peers of the Hemant Surgical?

Hemant Surgical's peers include Sastasundar Ven., Prevest Denpro, One Global Serv, Nureca, Bilcare, Take Solutions, Choksi Laborator, Royal Sense, QMS Medical, and Aakaar Medical. In terms of management risk, Hemant Surgical is rated as Good, with its 1-year return at -2.17%, higher than Take Solutions but lower than most peers.

Peers: The peers of Hemant Surgical are Sastasundar Ven., Prevest Denpro, One Global Serv, Nureca, Bilcare, Take Solutions, Choksi Laborator, Royal Sense, QMS Medical, and Aakaar Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at One Global Serv and Aakaar Medical, while Good management risk is found at Hemant Surgical. Average management risk is present at Prevest Denpro and QMS Medical, and Below Average management risk is noted at Sastasundar Ven., Nureca, Bilcare, Take Solutions, Choksi Laborator, and Royal Sense. Growth is Excellent at One Global Serv and Aakaar Medical, Average at Choksi Laborator, and Below Average at Hemant Surgical, Prevest Denpro, Nureca, Bilcare, Take Solutions, and Royal Sense. Excellent capital structure is seen at Sastasundar Ven., Prevest Denpro, One Global Serv, Nureca, Hemant Surgical, and Royal Sense, while Below Average capital structure is noted at Bilcare, Take Solutions, Choksi Laborator, and QMS Medical.<BR><BR>Return Snapshot: The peer with the highest 1-year return is One Global Serv at 89.49%, while the lowest is Take Solutions at -52.91%. Hemant Surgical's 1-year return is -2.17%, which is higher than Take Solutions but lower than the majority of its peers. Additionally, the six-month return is negative for Nureca, Take Solutions, and Royal Sense.

Who are in the management team of Hemant Surgical?

As of March 2023, the management team of Hemant Surgical includes Hanskumar Shamji Shah (Chairman & Managing Director), Hemant Praful Shah (Whole-time Director), Hans Kaushik Kumar Shah (Whole Time Director & CFO), Nehal Babu Kareliya (Director), Pooja (Independent Director), Sourabh Ajmera (Independent Director), and Meenal Ajmera (Company Secretary & Compliance Officer).

As of March 2023, the management team of Hemant Surgical includes the following individuals:<BR><BR>1. Hanskumar Shamji Shah - Chairman & Managing Director<BR>2. Hemant Praful Shah - Whole-time Director<BR>3. Hans Kaushik Kumar Shah - Whole Time Director & CFO<BR>4. Nehal Babu Kareliya - Director<BR>5. Pooja - Independent Director<BR>6. Sourabh Ajmera - Independent Director<BR>7. Meenal Ajmera - Company Secretary & Compliance Officer<BR><BR>These members play various roles within the company, contributing to its governance and operational management.

Who are the top shareholders of the Hemant Surgical?

The top shareholders of Hemant Surgical include Hanskumar Shamji Shah with 33.78%, followed by Carnelian Structural Shift Fund at 1.11%, and individual investors holding 20.87%. There are no pledged promoter holdings, and one Foreign Institutional Investor holds 0.39%.

The top shareholders of Hemant Surgical include the promoters, with Hanskumar Shamji Shah holding the largest share at 33.78%. There are no pledged promoter holdings, and the company has one Foreign Institutional Investor (FII) holding 0.39%. The highest public shareholder is Carnelian Structural Shift Fund, which holds 1.11%. Additionally, individual investors collectively hold 20.87% of the shares.

How big is Hemant Surgical?

As of 24th July, Hemant Surgical Industries Ltd has a market capitalization of 209.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 54.86 Cr and Total Assets of 96.64 Cr; however, recent financial data for Net Sales and Net Profit is unavailable.

As of 24th July, <BR><BR>Market Cap: Hemant Surgical Industries Ltd has a market capitalization of 209.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 54.86 Cr and Total Assets valued at 96.64 Cr.

How has been the historical performance of Hemant Surgical?

For the fiscal year ending March 2025, Hemant Surgical reported an operating income of 106.64 crore and a net profit of 8.04 crore, with total assets and liabilities both at 148.15 crore. The company had a cash flow from operating activities of 8.00 crore, resulting in a closing cash balance of 9.00 crore.

Answer:<BR>The historical performance of Hemant Surgical for the year ending March 2025 shows a total operating income of 106.64 crore, with a net profit after tax of 8.04 crore. The company reported an operating profit margin of 8.42% and a profit after tax margin of 7.54%. The earnings per share stood at 7.7, and the book value per share was 60.51. Total liabilities were recorded at 148.15 crore, with total assets also at 148.15 crore, indicating a balanced position. The cash flow from operating activities was 8.00 crore, while the net cash outflow for the period was 3.00 crore, resulting in a closing cash and cash equivalent of 9.00 crore.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Hemant Surgical achieved a total operating income of 106.64 crore, primarily driven by net sales. The company faced raw material costs of 94.26 crore, leading to a total expenditure of 97.66 crore, which resulted in an operating profit (PBDIT) of 14.10 crore. After accounting for interest and depreciation, the profit before tax was reported at 10.47 crore, culminating in a profit after tax of 8.04 crore. The company's total liabilities and total assets were both recorded at 148.15 crore, reflecting a stable financial position. The cash flow analysis indicated a cash flow from operating activities of 8.00 crore, but an overall net cash outflow of 3.00 crore, leaving a closing cash balance of 9.00 crore.

Is Hemant Surgical overvalued or undervalued?

As of December 1, 2025, Hemant Surgical is considered overvalued with a PE ratio of 43.61 and elevated EV ratios compared to peers, despite a strong year-to-date return of 115.49%.

As of 1 December 2025, Hemant Surgical's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company's current PE ratio stands at 43.61, while its EV to EBITDA ratio is 36.83, and the EV to Sales ratio is 3.14. These figures suggest that Hemant Surgical is trading at a premium compared to its earnings and sales, which raises concerns about its valuation.<BR><BR>In comparison to its peers, Hemant Surgical's valuation appears high, especially when juxtaposed with Apollo Hospitals, which has a PE ratio of 62.66 and an EV to EBITDA of 32.97, marking it as attractive. Other competitors like Narayana Hrudaya and Max Healthcare are also valued higher, with PE ratios of 45.9 and 77.91, respectively. Given these comparisons and the elevated ratios, Hemant Surgical is deemed overvalued in the current market context. Notably, the company has outperformed the Sensex with a year-to-date return of 115.49%, but this performance does not mitigate the concerns surrounding its current valuation.

Which are the latest news on Hemant Surgical?

Why is Hemant Surgical falling/rising?

As of 04-Dec, Hemant Surgical Industries Ltd's stock price is rising to 298.00, up 2.12%. This increase is driven by strong recent performance, significant investor participation, and trading above key moving averages.

As of 04-Dec, Hemant Surgical Industries Ltd's stock price is rising, currently at 298.00, reflecting a change of 6.2 (2.12%) upward. This increase can be attributed to several factors. Over the past week, the stock has outperformed the Sensex, gaining 14.77% compared to the benchmark's decline of 0.53%. Additionally, the stock has shown a strong performance over the last four days, with a cumulative return of 15.06%. <BR><BR>Today, the stock opened with a gain of 2.81% and reached an intraday high of Rs 300. The stock's performance is also supported by rising investor participation, as evidenced by a significant increase in delivery volume, which rose by 168.38% compared to the five-day average. Furthermore, the stock is trading above its 5-day, 20-day, 100-day, and 200-day moving averages, indicating a positive trend, although it is slightly below the 50-day moving average. Overall, these factors contribute to the upward movement in Hemant Surgical's stock price.